Table 4.
Effects of XCHD on MDA, ONOO - , VMA, LPS-P, ALP-A and ALP-C in the gut, liver and brain
| Groups | Dose (g.kg -1 ) | Gut (n) | Liver (n) | Brain (n) |
|---|---|---|---|---|
|
MDA (nmol/L/g) |
|
|
|
|
| Normal |
- |
5.48±1.78(6) |
300.86±29.16(6) |
68.34±13.22(6) |
| HCC |
- |
62.75±19.80(9)b |
318.21±23.27(6) |
126.39±30.92(8)b |
| HCC+LDSD |
- |
171.67±42.24d |
360.87±48.02(6)c |
180.72±27.05(8)d |
| XCHD |
8 |
58.69±17.99f |
319.75±19.28(7) |
127.06±24.33(8) |
|
ONOO
-
(mmol/L/g) |
|
|
|
|
| Normal |
- |
7.39±0.66(6) |
12.87±0.95(6) |
3.99±24.33(8)f |
| HCC |
- |
10.61±0.85(13)b |
16.40±0.80(13)b |
7.46±1.42(13)b |
| HCC+LDSD |
- |
15.19±1.78(9) |
19.86±0.80(9) |
12.90±0.48(9)d |
| XCHD |
8 |
10.31±1.12(14)f |
14.15±0.92(9) |
12.90±0.48(9) |
|
VMA (ug/ml/g) |
|
|
|
|
| Normal |
- |
6.78±1.09(6) |
32.46±5.64(6) |
1.76±0.96(6) |
| HCC |
- |
9.94±0.10b |
51.01±5.06(9)b |
3.99±0.46(6)b |
| HCC+LDSD |
- |
19.79±0.28(6)d |
86.66±5.06(9)d |
11.81±6.60(6)c |
| XCHD |
8 |
10.52±0.56(6)b |
74.38±10.20(14)f |
2.92±2.82(6)f |
|
LPS-P (mmol/L/g) |
|
|
|
|
| Normal |
- |
0.55±0.04(6) |
0.36±0.11(6) |
0.052±0.003(6) |
| HCC |
- |
0.66±0.06(6)b |
0.86±0.09(13)b |
0.060±0.004(6)b |
| HCC+LDSD |
- |
0.76±0.06(6)d |
1.30±0.43(6)d |
0.075±0.003(6)d |
| XCHD |
8 |
0.57±0.05(6)f |
0.71±0.12(14)f |
0.059±0.009(6)f |
|
ALP-A (μ) |
|
|
|
|
| Normal |
- |
131.98±30.86(6) |
140.17±8.74(6) |
29.60±2.41(6) |
| HCC |
- |
55.52±8.87(6)b |
53.70±7.78(6)b |
27.75±4.66(6)b |
| HCC+LDSD |
- |
35.94±8.77(6)d |
38.73±7.78(6)d |
20.27±±4.65(6)d |
| XCHD |
8 |
94.16±12.35(6)f |
64.13±7.52(6)f |
39.37±6.12(6)f |
|
ALP-C (%) |
|
|
|
|
| Normal |
- |
8.69±3.75(6) |
10.01±1.24(6) |
26.06.70(6) |
| HCC |
- |
47.32±14.75(6)b |
56.89±9.98(6)b |
37.84±6.95(6)b |
| HCC+LDSD |
- |
78.47±18.41(6)d |
75.37±14.87(6)c |
80.0±5.28(6)d |
| XCHD | 8 | 20.73±4.82(6)f | 32.73±4.49(6)f | 45.73±11.43(6) |
aP <0.05, bP<0.01 Compare with normal; cP <0.05, dP <0.01 Compare with HCC; eP <0.05, fP <0.01 Compare with HCC+LDSA.